Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis B

References

• cdc.gov [homepage on the Internet] Hepatitis B frequently asked questions for the public Centers for Disease Control 2008 [updated June 9, 2009; cited January 1, 2013]. Available from: http://www.cdc.gov/hepatitis/b/bFAQ.htm#statistics Accessed January 1, 2013
   Google Scholar
• http://www.who.int/en/ [homepage on the Internet] Hepatitis B fact sheet World Health Organization 2012 [cited January 1, 2013]. Available from: http://www.who.int/mediacentre/factsheets/fs204/en/ Accessed January 1, 2013
   Google Scholar
• Lok AS McMahon BJ American Association for the Study of Liver Diseases (AASLD) Practice Guidelines for Management of Chronic Hepatitis B: Update 2009 Hepatology 2009Available from: http://www.aasld.org/practiceguidelines/documents/bookmarked%20practice%20guidelines/chronic_hep_b_update_2009%208_24_2009.pdfAccessed January 1, 2013
   Google Scholar
• Schütte K Bornschein J Malfertheiner P Hepatocellular carcinoma – epidemiological trends and risk factors Dig Dis 2009 27 2 80 92 19546545
   PubMed Web of Science ®Google Scholar
• Wong DK Cheung AM O’Rourke K Naylor CD Detsky AS Heathcote J Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis Ann Intern Med 1993 119 4 312 323 8328741
   PubMed Web of Science ®Google Scholar
• Yuen MF Lai CL Treatment of chronic hepatitis B: Evolution over two decades J Gastroenterol Hepatol 2011 26 Suppl 1 138 143 21199525
   PubMed Web of Science ®Google Scholar
• Lai CL Chien RN Leung NW A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group N Engl J Med 1998 339 2 61 68 9654535
   PubMed Web of Science ®Google Scholar
• Chang TT Gish RG de Man R A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B N Engl J Med 2006 354 10 1001 1010 16525137
   PubMed Web of Science ®Google Scholar
• Lok AS Lai CL Leung N Long-term safety of lamivudine treatment in patients with chronic hepatitis B Gastroenterology 2003 125 6 1714 1722 14724824
   PubMed Web of Science ®Google Scholar
• Tenney DJ Rose RE Baldick CJ Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy Hepatology 2009 49 5 1503 1514 19280622
   PubMed Web of Science ®Google Scholar
• Liaw YF Leung N Kao JH Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update Hepatol Int 2008 2 3 263 283 19669255
   PubMed Web of Science ®Google Scholar
• Dienstag JL Schiff ER Wright TL Lamivudine as initial treatment for chronic hepatitis B in the United States N Engl J Med 1999 341 17 1256 1263 10528035
   PubMed Web of Science ®Google Scholar
• Zoulim F Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int 2011 31 Suppl 1 111 116 21205147
   PubMed Web of Science ®Google Scholar
• Fung J Lai CL Seto WK Yuen MF Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B J Antimicrob Chemother 2011 66 12 2715 2725 21965435
   PubMed Web of Science ®Google Scholar
• Yuen MF Sablon E Hui CK Yuan HJ Decraemer H Lai CL Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy Hepatology 2001 34 4 Pt 1 785 791 11584376
   PubMed Web of Science ®Google Scholar
• Fournier C Zoulim F Antiviral therapy of chronic hepatitis B: prevention of drug resistance Clin Liver Dis 2007 11 4 869 892 ix 17981233
   PubMedGoogle Scholar
• Wang C Fan R Sun J Hou J Prevention and management of drug resistant hepatitis B virus infections J Gastroenterol Hepatol 2012 27 9 1432 1440 22694205
   PubMed Web of Science ®Google Scholar
• Marcellin P Sung J Piratvisuth T Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon Liver Int 2010 30 5 657 668 20158610
   PubMed Web of Science ®Google Scholar
• Lai CL Gane E Liaw YF Telbivudine versus lamivudine in patients with chronic hepatitis B N Engl J Med 2007 357 25 2576 2588 18094378
   PubMed Web of Science ®Google Scholar
• Gane EJ The Roadmap concept: using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis B Hepatol Int 2008 2 3 304 307 19669258
   PubMed Web of Science ®Google Scholar
• Hsieh TH Tseng TC Liu CJ Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C Antivir Ther (Lond) 2009 14 8 1157 1163 20032545
   PubMed Web of Science ®Google Scholar
• Mello FC Fernandes CA Gomes Sde A Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes Mem Inst Oswaldo Cruz 2012 107 3 317 325 22510826
   PubMed Web of Science ®Google Scholar
• Benhamou Y Bochet M Thibault V Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients Hepatolog y 1999 30 5 1302 1306
   PubMed Web of Science ®Google Scholar
• Kosi L Reiberger T Payer BA Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients J Viral Hepat 2012 19 11 801 810 23043387
   PubMed Web of Science ®Google Scholar
• Sueki R Maekawa S Miura M Correlation between pretreatment viral sequences and the emergence of lamivudine resistance in hepatitis B virus infection J Med Virol 2012 84 9 1360 1368 22825814
   PubMed Web of Science ®Google Scholar
• Chen CH Lee CM Tung WC Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance J Hepatol 2010 52 4 478 485 20185198
   PubMed Web of Science ®Google Scholar
• Zhao J Guo Y Yan Z Liang P Zhang J Liu Y The natural YMDD mutations of hepatitis B virus in Western China Scand J Infect Dis 2012 44 1 44 47 21851334
   PubMed Web of Science ®Google Scholar
• Tan YW Ge GH Zhao W YMDD motif mutations in chronic hepatitis B antiviral treatment naïve patients: a multi-center study Braz J Infect Dis 2012 16 3 250 255 22729192
   PubMed Web of Science ®Google Scholar
• Tan Y Ding K Su J The naturally occurring YMDD mutation among patients chronically infected HBV and untreated with lamivudine: a systematic review and meta-analysis PLoS ONE 2012 7 3 e32789 22479339
   PubMed Web of Science ®Google Scholar
• Lee SH Kim HS Byun IS Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy J Med Virol 2012 84 2 217 222 22170540
   PubMed Web of Science ®Google Scholar
• Thai H Campo DS Lara J Convergence and coevolution of hepatitis B virus drug resistance Nat Commun 2012 3 789 22510694
   PubMed Web of Science ®Google Scholar
• Svicher V Cento V Salpini R Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development Dig Liver Dis 2011 43 12 975 983 21831732
   PubMedGoogle Scholar
• Margeridon-Thermet S Shulman NS Ahmed A Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients J Infect Dis 2009 199 9 1275 1285 19301976
   PubMed Web of Science ®Google Scholar
• Solmone M Vincenti D Prosperi MC Bruselles A Ippolito G Capobianchi MR Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen J Virol 2009 83 4 1718 1726 19073746
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver EASL clinical practice guidelines: Management of chronic hepatitis B virus infection J Hepatol 2012 57 1 167 185 22436845
   PubMed Web of Science ®Google Scholar
• Papatheodoridis GV Cholongitas E Archimandritis AJ Burroughs AK Current management of hepatitis B virus infection before and after liver transplantation Liver Int 2009 29 9 1294 1305 19619264
   PubMed Web of Science ®Google Scholar
• Buchanan C Tran TT Current status of liver transplantation for hepatitis B virus Clin Liver Dis 2011 15 4 753 764 22032527
   PubMed Web of Science ®Google Scholar
• Rapti IN Hadziyannis SJ Treatment of special populations with chronic hepatitis B infection Expert Rev Gastroenterol Hepatol 2011 5 3 323 339 21651351
   PubMed Web of Science ®Google Scholar
• Haynes RB Ackloo E Sahota N McDonald HP Yao X Interventions for enhancing medication adherence [review] Cochrane Database Syst Rev 2008 2 CD000011 18425859
   PubMed Web of Science ®Google Scholar
• Bonner JE Barritt AS Fried MW Evon DM Tangible resources for preparing patients for antiviral therapy for chronic hepatitis C Dig Dis Sci 2012 57 6 1439 1444 22488633
   PubMed Web of Science ®Google Scholar
• Fan XH Geng JZ Wang LF De novo combination therapy with lamivudine and adefovir dipivoxil in chronic hepatitis B patients World J Gastroenterol 2011 17 43 4804 4809 22147982
   PubMed Web of Science ®Google Scholar
• Wang LC Chen EQ Cao J De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naïve HBeAg-negative chronic hepatitis B patients Hepatol Int 2011 5 2 671 676 21484140
   PubMed Web of Science ®Google Scholar
• Perrillo R Hann HW Mutimer D Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus Gastroenterology 2004 126 1 81 90 14699490
   PubMed Web of Science ®Google Scholar
• Perrillo RP Hann HW Schiff E Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance Hepatol Int 2011 5 2 654 663 21484148
   PubMed Web of Science ®Google Scholar
• Sung JJ Lai JY Zeuzem S Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B J Hepatol 2008 48 5 728 735 18329126
   PubMed Web of Science ®Google Scholar
• Rapti I Dimou E Mitsoula P Hadziyannis SJ Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B Hepatology 2007 45 2 307 313 17256746
   PubMed Web of Science ®Google Scholar
• Zhao P Wang C Huang L Xu D Li T Comparison of rescue strategies in lamivudine-resistant patients with chronic hepatitis B Antiviral Res 2012 96 2 100 104 22960601
   PubMed Web of Science ®Google Scholar
• Lai CL Shouval D Lok AS Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B N Engl J Med 2006 354 10 1011 1020 16525138
   PubMed Web of Science ®Google Scholar
• Sherman M Yurdaydin C Sollano J Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B Gastroenterology 2006 130 7 2039 2049 16762627
   PubMed Web of Science ®Google Scholar
• Sherman M Yurdaydin C Simsek H Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks Hepatology 2008 48 1 99 108 18537189
   PubMed Web of Science ®Google Scholar
• Kim HJ Park JH Park DI Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy J Gastroenterol Hepatol 2010 25 8 1374 1380 20659226
   PubMed Web of Science ®Google Scholar
• Ryu HJ Lee JM Ahn SH Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B J Med Virol 2010 82 11 1835 1842 20872709
   PubMed Web of Science ®Google Scholar
• Sheng YJ Liu JY Tong SW Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis Virol J 2011 8 393 21824397
   PubMed Web of Science ®Google Scholar
• Ha M Zhang G Diao S Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy Intern Med 2012 51 12 1509 1515 22728482
   PubMed Web of Science ®Google Scholar
• Lim YS Lee JY Lee D Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir Antimicrob Agents Chemother 2012 56 6 2941 2947 22430972
   PubMed Web of Science ®Google Scholar
• Marcellin P Heathcote EJ Buti M Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B N Engl J Med 2008 359 23 2442 2455 19052126
   PubMed Web of Science ®Google Scholar
• van Bömmel F de Man RA Wedemeyer H Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues Hepatology 2010 51 1 73 80 19998272
   PubMed Web of Science ®Google Scholar
• van Bömmel F Wünsche T Mauss S Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection Hepatology 2004 40 6 1421 1425 15565615
   PubMed Web of Science ®Google Scholar
• Ong A Wong VW Wong GL Chan HY Tse CH Chan HL Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir Aliment Pharmacol Ther 2011 34 8 972 981 21883327
   PubMed Web of Science ®Google Scholar
• Allen MI Deslauriers M Andrews CW Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group Hepatology 1998 27 6 1670 1677 9620341
   PubMed Web of Science ®Google Scholar
• Tenney DJ Levine SM Rose RE Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine Antimicrob Agents Chemother 2004 48 9 3498 3507 15328117
   PubMed Web of Science ®Google Scholar
• Lai CL Leung N Teo EK A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B Gastroenterology 2005 129 2 528 536 16083710
   PubMed Web of Science ®Google Scholar
• Locarnini S Hatzakis A Heathcote J Management of antiviral resistance in patients with chronic hepatitis B Antivir Ther (Lond) 2004 9 5 679 693 15535405
   PubMed Web of Science ®Google Scholar